Published in J Gastroenterol on May 25, 2007
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag (2008) 1.49
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol (2012) 1.04
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci (2009) 0.95
Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol (2014) 0.93
Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol (2012) 0.85
Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis. World J Gastroenterol (2014) 0.80
Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. World J Hepatol (2010) 0.78
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J Gastroenterol (2013) 0.78
Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig (2013) 0.77
Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis. Int J Mol Sci (2016) 0.75
Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol (2017) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care (1998) 8.29
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61
Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis (2001) 4.44
Abdominal fat: standardized technique for measurement at CT. Radiology (1999) 4.25
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology (1988) 2.20
Nonalcoholic steatohepatitis. Gastroenterology (2001) 2.12
Appropriateness of liver biopsy. Can J Gastroenterol (2000) 1.65
Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol (2003) 1.39
Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol (2005) 1.30
Clinical aspects of fatty liver disease. Semin Liver Dis (2004) 1.11
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand J Clin Lab Invest (1992) 0.92
Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology (1992) 0.91
Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res (2002) 0.90
[Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future]. Gastroenterol Clin Biol (2002) 0.86
Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol (1992) 0.81
Treatment of non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 0.81
Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology (1994) 0.80
Noninvasive determination of liver collagen content in chronic hepatitis. Multivariate regression modeling with blood chemical parameters as variables. J Gastroenterol (1997) 0.79
Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease. Hepatology (1996) 0.77
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 9.79
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest (2004) 5.29
Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem (2002) 4.79
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem (2002) 4.16
Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab (2007) 3.43
PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol (2002) 3.37
Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res (2007) 3.02
Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ (2013) 2.74
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology (2003) 2.65
Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol (2011) 2.44
Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion (2009) 2.43
Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab (2011) 2.42
Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol (2007) 2.29
Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc (2007) 2.23
FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res (2007) 2.21
Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem (2004) 2.15
Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther (2012) 2.15
Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol (2009) 2.05
Variations in the FTO gene are associated with severe obesity in the Japanese. J Hum Genet (2008) 2.03
Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem (2006) 1.93
Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol (2002) 1.92
Nod factor/nitrate-induced CLE genes that drive HAR1-mediated systemic regulation of nodulation. Plant Cell Physiol (2008) 1.92
A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology (2003) 1.91
Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest (2004) 1.88
Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di- and trimethylation. Genes Dev (2008) 1.87
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab (2008) 1.86
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci U S A (2009) 1.80
Potent antitumor activity of interleukin-27. Cancer Res (2004) 1.80
Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology (2010) 1.71
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb (2008) 1.70
Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc (2010) 1.70
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog (2010) 1.69
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J Gastroenterol (2005) 1.69
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol (2009) 1.69
Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci (2008) 1.69
Ethylene promotes submergence-induced expression of OsABA8ox1, a gene that encodes ABA 8'-hydroxylase in rice. Plant Cell Physiol (2007) 1.63
Ly6C+ Ly6G- Myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J Neurochem (2013) 1.60
Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer (2005) 1.58
miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci (2011) 1.57
The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.57
Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol (2007) 1.56
Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun (2007) 1.55
Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol (2004) 1.55
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res (2007) 1.55
Sema3A regulates bone-mass accrual through sensory innervations. Nature (2013) 1.53
The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol (2004) 1.52